{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:41:49Z","timestamp":1791758509933,"version":"4.3.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>Over the last decade, the implementation of multigene panels for hereditary tumor syndrome has increased at our institution (Inselspital, University Hospital Berne, Switzerland). The aim of this study was to determine the prevalence of variants of unknown significance (VUS) in patients with suspected Lynch syndrome and suspected hereditary breast and ovarian cancer syndrome, the latter in connection with the trend toward ordering larger gene panels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Retrospectively collected data from 1057 patients at our institution showed at least one VUS in 126 different cases (11.9%). In patients undergoing genetic testing for\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      , the prevalence of VUS was 6%. When\u2009&lt;\u200910 additional genes were tested in addition to\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      , the prevalence increased to 13.8%, and 31.8% for\u2009&gt;\u200910 additional genes, respectively. The gene most frequently affected with a VUS was\n                      <jats:italic>ATM<\/jats:italic>\n                      . 6% of our patients who were tested for Lynch syndrome had a VUS result in either\n                      <jats:italic>MLH1, MSH2<\/jats:italic>\n                      or\n                      <jats:italic>MSH6<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our data demonstrate that panel testing statistically significantly increases VUS rates due to variants in non-\n                      <jats:italic>BRCA<\/jats:italic>\n                      genes. Good genetic counseling before and after obtaining results is therefore particularly important when conducting multigene panels to minimize patient uncertainty due to VUS results.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12920-023-01437-7","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T09:03:07Z","timestamp":1673859787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study"],"prefix":"10.1186","volume":"16","author":[{"given":"Felicia","family":"Adam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Fluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Scherz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Rabaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"issue":"3","key":"1437_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1188\/15.ONF.316-318","volume":"42","author":"S Mahon","year":"2015","unstructured":"Mahon S. Management of patients with a genetic variant of unknown significance. Oncol Nurs Forum. 2015;42(3):316\u20138. https:\/\/doi.org\/10.1188\/15.ONF.316-318.","journal-title":"Oncol Nurs Forum"},{"issue":"10","key":"1437_CR2","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1200\/JCO.2012.46.9403","volume":"31","author":"SM Domchek","year":"2013","unstructured":"Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: Out on the high wire without a net? J Clin Oncol. 2013;31(10):1267\u201370. https:\/\/doi.org\/10.1200\/JCO.2012.46.9403.","journal-title":"J Clin Oncol"},{"issue":"38","key":"1437_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/jncimonographs\/lgn001","volume":"2008","author":"NM Lindor","year":"2008","unstructured":"Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer susceptibility syndromes. JNCI Monogr. 2008;2008(38):3\u201393. https:\/\/doi.org\/10.1093\/jncimonographs\/lgn001.","journal-title":"JNCI Monogr."},{"key":"1437_CR4","doi-asserted-by":"publisher","unstructured":"Genetics, genomics, and cancer risk assessment\u2014Weitzel\u20142011\u2014CA: A Cancer Journal for Clinicians - Wiley Online Library. Accessed March 21, 2022. https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.3322\/caac.20128.","DOI":"10.3322\/caac.20128"},{"issue":"5182","key":"1437_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66\u201371. https:\/\/doi.org\/10.1126\/science.7545954.","journal-title":"Science"},{"issue":"6559","key":"1437_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789\u201392. https:\/\/doi.org\/10.1038\/378789a0.","journal-title":"Nature"},{"issue":"5182","key":"1437_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1126\/science.7939630","volume":"266","author":"PA Futreal","year":"1994","unstructured":"Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;266(5182):120\u20132. https:\/\/doi.org\/10.1126\/science.7939630.","journal-title":"Science"},{"issue":"3","key":"1437_CR8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1056\/NEJM199601183340311","volume":"334","author":"FS Collins","year":"1996","unstructured":"Collins FS. BRCA1\u2014lots of mutations, lots of dilemmas. N Engl J Med. 1996;334(3):186\u20138. https:\/\/doi.org\/10.1056\/NEJM199601183340311.","journal-title":"N Engl J Med"},{"issue":"11","key":"1437_CR9","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/humu.20880","volume":"29","author":"SE Plon","year":"2008","unstructured":"Plon SE, Eccles DM, Easton D, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29(11):1282\u201391. https:\/\/doi.org\/10.1002\/humu.20880.","journal-title":"Hum Mutat"},{"issue":"28","key":"1437_CR10","doi-asserted-by":"publisher","first-page":"12629","DOI":"10.1073\/pnas.1007983107","volume":"107","author":"T Walsh","year":"2010","unstructured":"Walsh T, Lee MK, Casadei S, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci. 2010;107(28):12629\u201333. https:\/\/doi.org\/10.1073\/pnas.1007983107.","journal-title":"Proc Natl Acad Sci"},{"key":"1437_CR11","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic\/familial high risk assessment: Breast, Ovarian, and Pancreatic. Version 2.2022. NCCN. Published March 9, 2022. Accessed April 4, 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-detail."},{"key":"1437_CR12","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic\/familial high risk assessment: Colorectal. Version 1.2021. NCCN. Published May 1, 2021. Accessed April 4, 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-detail"},{"key":"1437_CR13","unstructured":"Chappuis PO, Bolliger B, B\u00fcrki N, Buser K, Heini K. Genetic predisposition to breast and ovarian cancer. :6."},{"key":"1437_CR14","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2021.w30038","author":"S Stoll","year":"2021","unstructured":"Stoll S, Unger S, Azzarello-Burri S, et al. Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer: Swiss Group for Clinical Cancer Research (SAKK) N for CPT and C (CPTC), ed. Swiss Med Wkly. 2021. https:\/\/doi.org\/10.4414\/smw.2021.w30038.","journal-title":"Swiss Med Wkly"},{"issue":"19","key":"1437_CR15","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1200\/JCO.2016.69.6120","volume":"35","author":"F Kastrinos","year":"2017","unstructured":"Kastrinos F, Uno H, Ukaegbu C, et al. Development and validation of the PREMM5 model for comprehensive risk assessment of lynch syndrome. J Clin Oncol. 2017;35(19):2165\u201372. https:\/\/doi.org\/10.1200\/JCO.2016.69.6120.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1437_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/jmedgenet-2018-105872","volume":"56","author":"AB Spurdle","year":"2019","unstructured":"Spurdle AB, Greville-Heygate S, Antoniou AC, et al. Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. J Med Genet. 2019;56(6):347\u201357. https:\/\/doi.org\/10.1136\/jmedgenet-2018-105872.","journal-title":"J Med Genet"},{"issue":"2","key":"1437_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/ng.2854","volume":"46","author":"BA Thompson","year":"2014","unstructured":"Thompson BA, Spurdle AB, Plazzer JP, et al. Application of a five-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants lodged on the InSiGHT locus-specific database. Nat Genet. 2014;46(2):107\u201315. https:\/\/doi.org\/10.1038\/ng.2854.","journal-title":"Nat Genet"},{"key":"1437_CR18","unstructured":"ClinVar - ClinGen | Clinical Genome Resource. Accessed October 30, 2022. https:\/\/www.clinicalgenome.org\/data-sharing\/clinvar\/."},{"issue":"5","key":"1437_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"issue":"5","key":"1437_CR20","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1086\/521032","volume":"81","author":"DF Easton","year":"2007","unstructured":"Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 2007;81(5):873\u201383. https:\/\/doi.org\/10.1086\/521032.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"1437_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1158\/0008-5472.CAN-21-1845","volume":"82","author":"RACM Boonen","year":"2022","unstructured":"Boonen RACM, Wiegant WW, Celosse N, et al. Functional analysis identifies damaging CHEK2 missense variants associated with increased cancer risk. Cancer Res. 2022;82(4):615\u201331. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1845.","journal-title":"Cancer Res"},{"issue":"6","key":"1437_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1200\/JCO.18.00474","volume":"37","author":"AY Shuen","year":"2019","unstructured":"Shuen AY, Lanni S, Panigrahi GB, et al. Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue. J Clin Oncol. 2019;37(6):461\u201370. https:\/\/doi.org\/10.1200\/JCO.18.00474.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1437_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/GIM.0b013e318207f564","volume":"13","author":"SE Plon","year":"2011","unstructured":"Plon SE, Cooper HP, Parks B, et al. Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med. 2011;13(2):148\u201354. https:\/\/doi.org\/10.1097\/GIM.0b013e318207f564.","journal-title":"Genet Med"},{"key":"1437_CR24","doi-asserted-by":"publisher","first-page":"viii69","DOI":"10.1093\/annonc\/mdt312","volume":"24","author":"S Richter","year":"2013","unstructured":"Richter S, Haroun I, Graham TC, Eisen A, Kiss A, Warner E. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. Ann Oncol. 2013;24:viii69\u201374. https:\/\/doi.org\/10.1093\/annonc\/mdt312.","journal-title":"Ann Oncol"},{"issue":"5","key":"1437_CR25","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/cge.12097","volume":"84","author":"J Culver","year":"2013","unstructured":"Culver J, Brinkerhoff C, Clague J, et al. Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress. Clin Genet. 2013;84(5):464\u201372. https:\/\/doi.org\/10.1111\/cge.12097.","journal-title":"Clin Genet"},{"issue":"12","key":"1437_CR26","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/GIM.0b013e318226fc15","volume":"13","author":"ML Murray","year":"2011","unstructured":"Murray ML, Cerrato F, Bennett RL, Jarvik GP. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genet Med. 2011;13(12):998\u20131005. https:\/\/doi.org\/10.1097\/GIM.0b013e318226fc15.","journal-title":"Genet Med"},{"issue":"23","key":"1437_CR27","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402. https:\/\/doi.org\/10.1001\/jama.2017.7112.","journal-title":"JAMA"},{"issue":"12","key":"1437_CR28","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/cancers10120524","volume":"10","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J. BRCA mutations and breast cancer prevention. Cancers. 2018;10(12):524. https:\/\/doi.org\/10.3390\/cancers10120524.","journal-title":"Cancers"},{"issue":"1","key":"1437_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/bcr6","volume":"1","author":"DF Easton","year":"1999","unstructured":"Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res. 1999;1(1):14. https:\/\/doi.org\/10.1186\/bcr6.","journal-title":"Breast Cancer Res"},{"issue":"19","key":"1437_CR30","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","volume":"32","author":"AW Kurian","year":"2014","unstructured":"Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014;32(19):2001\u20139. https:\/\/doi.org\/10.1200\/JCO.2013.53.6607.","journal-title":"J Clin Oncol"},{"issue":"44","key":"1437_CR31","doi-asserted-by":"publisher","first-page":"18032","DOI":"10.1073\/pnas.1115052108","volume":"108","author":"T Walsh","year":"2011","unstructured":"Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci. 2011;108(44):18032\u20137. https:\/\/doi.org\/10.1073\/pnas.1115052108.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"1437_CR32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2(4):482\u201390. https:\/\/doi.org\/10.1001\/jamaoncol.2015.5495.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1437_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.29010","volume":"121","author":"N Tung","year":"2015","unstructured":"Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121(1):25\u201333. https:\/\/doi.org\/10.1002\/cncr.29010.","journal-title":"Cancer"},{"issue":"5","key":"1437_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jmoldx.2015.04.009","volume":"17","author":"SE Lincoln","year":"2015","unstructured":"Lincoln SE, Kobayashi Y, Anderson MJ, et al. A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients. J Mol Diagn. 2015;17(5):533\u201344. https:\/\/doi.org\/10.1016\/j.jmoldx.2015.04.009.","journal-title":"J Mol Diagn"},{"issue":"11","key":"1437_CR35","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/gim.2014.40","volume":"16","author":"H LaDuca","year":"2014","unstructured":"LaDuca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med. 2014;16(11):830\u20137. https:\/\/doi.org\/10.1038\/gim.2014.40.","journal-title":"Genet Med"},{"issue":"8","key":"1437_CR36","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/gim.2014.176","volume":"17","author":"KN Maxwell","year":"2015","unstructured":"Maxwell KN, Wubbenhorst B, D\u2019Andrea K, et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1\/2-negative patients with early-onset breast cancer. Genet Med. 2015;17(8):630\u20138. https:\/\/doi.org\/10.1038\/gim.2014.176.","journal-title":"Genet Med"},{"key":"1437_CR37","unstructured":"Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals. 11."},{"key":"1437_CR38","unstructured":"Saam J, Burbidge L, Bowles K. Decline in rate of BRCA1\/2 variants of uncertain significance: 2002\u20132008. Poster presented at: 27th Annual Education Conference of the National Society of Genetic Counselors; 2008; Los Angeles."},{"issue":"3","key":"1437_CR39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/cge.12315","volume":"86","author":"J Eggington","year":"2014","unstructured":"Eggington J, Bowles K, Moyes K, et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet. 2014;86(3):229\u201337. https:\/\/doi.org\/10.1111\/cge.12315.","journal-title":"Clin Genet"},{"issue":"10","key":"1437_CR40","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMra012242","volume":"348","author":"HT Lynch","year":"2003","unstructured":"Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10):919\u201332. https:\/\/doi.org\/10.1056\/NEJMra012242.","journal-title":"N Engl J Med"},{"issue":"21","key":"1437_CR41","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1056\/NEJM199805213382101","volume":"338","author":"LA Aaltonen","year":"1998","unstructured":"Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338(21):1481\u20137. https:\/\/doi.org\/10.1056\/NEJM199805213382101.","journal-title":"N Engl J Med"},{"issue":"4","key":"1437_CR42","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1053\/gast.2001.27996","volume":"121","author":"WS Samowitz","year":"2001","unstructured":"Samowitz WS, Curtin K, Lin HH, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology. 2001;121(4):830\u20138. https:\/\/doi.org\/10.1053\/gast.2001.27996.","journal-title":"Gastroenterology"},{"issue":"1","key":"1437_CR43","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/ng.283","volume":"41","author":"MJL Ligtenberg","year":"2009","unstructured":"Ligtenberg MJL, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3\u2032 exons of TACSTD1. Nat Genet. 2009;41(1):112\u20137. https:\/\/doi.org\/10.1038\/ng.283.","journal-title":"Nat Genet"},{"issue":"6","key":"1437_CR44","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/gutjnl-2012-304356","volume":"62","author":"HFA Vasen","year":"2013","unstructured":"Vasen HFA, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62(6):812\u201323. https:\/\/doi.org\/10.1136\/gutjnl-2012-304356.","journal-title":"Gut"},{"issue":"9","key":"1437_CR45","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1200\/JCO.2011.39.5590","volume":"30","author":"AK Win","year":"2012","unstructured":"Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30(9):958\u201364. https:\/\/doi.org\/10.1200\/JCO.2011.39.5590.","journal-title":"J Clin Oncol"},{"issue":"4B","key":"1437_CR46","first-page":"1635","volume":"14","author":"P Watson","year":"1994","unstructured":"Watson P, Lynch HT. The tumor spectrum in HNPCC. Anticancer Res. 1994;14(4B):1635\u20139.","journal-title":"Anticancer Res"},{"issue":"2","key":"1437_CR47","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/(sici)1097-0215(19990412)81:2<214::aid-ijc8>3.0.co;2-l","volume":"81","author":"M Aarnio","year":"1999","unstructured":"Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81(2):214\u20138. https:\/\/doi.org\/10.1002\/(sici)1097-0215(19990412)81:2%3c214::aid-ijc8%3e3.0.co;2-l.","journal-title":"Int J Cancer"},{"issue":"1","key":"1437_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","volume":"22","author":"M Dominguez-Valentin","year":"2020","unstructured":"Dominguez-Valentin M, Sampson JR, Sepp\u00e4l\u00e4 TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2020;22(1):15\u201325. https:\/\/doi.org\/10.1038\/s41436-019-0596-9.","journal-title":"Genet Med"},{"issue":"3","key":"1437_CR49","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1136\/gutjnl-2019-319915","volume":"69","author":"KJ Monahan","year":"2020","unstructured":"Monahan KJ, Bradshaw N, Dolwani S, et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)\/Association of Coloproctology of Great Britain and Ireland (ACPGBI)\/United Kingdom Cancer Genetics Group (UKCGG). Gut. 2020;69(3):411\u201344. https:\/\/doi.org\/10.1136\/gutjnl-2019-319915.","journal-title":"Gut"},{"key":"1437_CR50","unstructured":"Genpanel Diagnostik \u2013 Genetica AG. Accessed March 14, 2022. https:\/\/genetica-ag.ch\/genpanel-diagnostik\/."},{"key":"1437_CR51","unstructured":"DGVademecum. Accessed March 14, 2022. https:\/\/dgvademecum.ksa.ch\/."},{"issue":"31","key":"1437_CR52","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","volume":"33","author":"ME Robson","year":"2015","unstructured":"Robson ME, Bradbury AR, Arun B, et al. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015;33(31):3660\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.63.0996.","journal-title":"J Clin Oncol"},{"key":"1437_CR53","unstructured":"Liste der Analysen - Spital Wallis. Accessed April 6, 2022. https:\/\/www.spitalwallis.ch\/gesundheitsfachpersonal\/zentralinstitut-der-spitaeler\/laboratorien\/fachbereiche\/genetik\/liste-der-analysen."},{"key":"1437_CR54","unstructured":"Liste des panels de g\u00e8nes. Accessed April 6, 2022. https:\/\/www.hug.ch\/medecine-genetique\/liste-panels-genes."},{"key":"1437_CR55","unstructured":"Universit\u00e4tsspital Basel. Auftrag Lynch-Syndrom. Accessed March 14, 2022. https:\/\/www.unispital-basel.ch\/fileadmin\/unispitalbaselch\/Lehre_Forschung\/Dep_Biomedizin\/Medizinische_Genetik\/Labordiagnostik\/Auftragsformulare\/Auftrag_Lynch-Syndrom_HNPCC_18_11_2015.pdf."},{"key":"1437_CR56","unstructured":"SAS SAS. Swiss Accreditation Service SAS. Accessed October 30, 2022. https:\/\/www.sas.admin.ch\/sas\/en\/home.html."},{"key":"1437_CR57","unstructured":"Daly MJ. gnomAD Genome Aggregation Database. Accessed October 30, 2022. https:\/\/gnomad.broadinstitute.org\/."},{"issue":"4","key":"1437_CR58","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","volume":"99","author":"NM Ioannidis","year":"2016","unstructured":"Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016;99(4):877\u201385. https:\/\/doi.org\/10.1016\/j.ajhg.2016.08.016.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1437_CR59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1053\/j.gastro.2010.08.021","volume":"140","author":"F Kastrinos","year":"2011","unstructured":"Kastrinos F, Steyerberg EW, Mercado R, et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology. 2011;140(1):73\u201381. https:\/\/doi.org\/10.1053\/j.gastro.2010.08.021.","journal-title":"Gastroenterology"},{"key":"1437_CR60","unstructured":"Switzerland Population and Demographics from Switzerland | - CountryReports. Accessed October 30, 2022. https:\/\/www.countryreports.org\/country\/Switzerland\/population.htm."},{"issue":"10","key":"1437_CR61","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1245\/s10434-017-5963-7","volume":"24","author":"E O\u2019Leary","year":"2017","unstructured":"O\u2019Leary E, Iacoboni D, Holle J, et al. Expanded gene panel use for women with breast cancer: identification and intervention beyond breast cancer risk. Ann Surg Oncol. 2017;24(10):3060\u20136. https:\/\/doi.org\/10.1245\/s10434-017-5963-7.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"1437_CR62","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.6004\/jnccn.2014.0128","volume":"12","author":"MJ Hall","year":"2014","unstructured":"Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw. 2014;12(9):1339\u201346. https:\/\/doi.org\/10.6004\/jnccn.2014.0128.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"1437_CR63","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","volume":"1","author":"A Desmond","year":"2015","unstructured":"Desmond A, Kurian AW, Gabree M, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 2015;1(7):943\u201351. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2690.","journal-title":"JAMA Oncol"},{"issue":"10","key":"1437_CR64","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1245\/s10434-015-4754-2","volume":"22","author":"NS Kapoor","year":"2015","unstructured":"Kapoor NS, Curcio LD, Blakemore CA, et al. Multigene panel testing detects equal rates of pathogenic BRCA1\/2 mutations and has a higher diagnostic yield compared to limited BRCA1\/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol. 2015;22(10):3282\u20138. https:\/\/doi.org\/10.1245\/s10434-015-4754-2.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1437_CR65","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10897-014-9796-2","volume":"24","author":"J Doherty","year":"2015","unstructured":"Doherty J, Bonadies DC, Matloff ET. Testing for hereditary breast cancer: panel or targeted testing? Experience from a clinical cancer genetics practice. J Genet Couns. 2015;24(4):683\u20137. https:\/\/doi.org\/10.1007\/s10897-014-9796-2.","journal-title":"J Genet Couns"},{"key":"1437_CR66","doi-asserted-by":"publisher","unstructured":"McVean GA, Altshuler (Co-Chair) DM, Durbin (Co-Chair) RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56\u201365. https:\/\/doi.org\/10.1038\/nature11632","DOI":"10.1038\/nature11632"},{"issue":"1","key":"1437_CR67","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13073-019-0683-1","volume":"11","author":"DM Kanavy","year":"2019","unstructured":"Kanavy DM, McNulty SM, Jairath MK, et al. Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels. Genome Med. 2019;11(1):77. https:\/\/doi.org\/10.1186\/s13073-019-0683-1.","journal-title":"Genome Med"},{"issue":"2","key":"1437_CR68","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/gim.2017.96","volume":"20","author":"JL Caswell-Jin","year":"2018","unstructured":"Caswell-Jin JL, Gupta T, Hall E, et al. Racial\/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genet Med. 2018;20(2):234\u20139. https:\/\/doi.org\/10.1038\/gim.2017.96.","journal-title":"Genet Med"},{"issue":"12","key":"1437_CR69","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1136\/gut.2005.090159","volume":"55","author":"RC Niessen","year":"2006","unstructured":"Niessen RC, Berends MJW, Wu Y, et al. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer. Gut. 2006;55(12):1781\u20138. https:\/\/doi.org\/10.1136\/gut.2005.090159.","journal-title":"Gut"},{"issue":"7","key":"1437_CR70","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/humu.20502","volume":"28","author":"MO Woods","year":"2007","unstructured":"Woods MO, Williams P, Careen A, et al. A new variant database for mismatch repair genes associated with Lynch syndrome. Hum Mutat. 2007;28(7):669\u201373. https:\/\/doi.org\/10.1002\/humu.20502.","journal-title":"Hum Mutat"},{"issue":"4","key":"1437_CR71","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/gcc.20642","volume":"48","author":"RC Niessen","year":"2009","unstructured":"Niessen RC, Kleibeuker JH, Westers H, et al. PMS2 involvement in patients suspected of Lynch syndrome. Genes Chromosomes Cancer. 2009;48(4):322\u20139. https:\/\/doi.org\/10.1002\/gcc.20642.","journal-title":"Genes Chromosomes Cancer"},{"key":"1437_CR72","unstructured":"Eggington JM, Burbidge LA, Roa B, et al. Current Variant of Uncertain Significance Rates in BRCA1\/2 and Lynch Syndrome Testing. Poster presented at: American College of Medical Genetics and Genomics Annual Meeting; March 2012; Myriad Genetic Laboratories, Inc., 320 Wakara Way, Salt Lake City, Utah 84108, USA."}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-023-01437-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T09:04:51Z","timestamp":1673859891000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-023-01437-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1186\/s12920-023-01437-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1893202\/v1","asserted-by":"object"}]},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Swiss Ethics Commission: Kantonale\u00a0Ethikkommission\u00a0des Kanton Bern, Switzerland. Patients\/Probands gave informed consent to tests as well as to use of data\/material for further anonymous use including publication according to local and national guidelines. All methods were carried out in accordance with relevant guidelines and regulation (Declaration of Helsinki).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}